Marten Steen
Directeur/Membre du Conseil chez Healthneed AB
Provenance du réseau au premier degré de Marten Steen
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
University of Lund
100
| College/University | Other Consumer Services | 100 |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland.
20
| Subsidiary | Investment Managers | 20 |
| Public Company | Pharmaceuticals: Major | 19 | |
| Subsidiary | Pharmaceuticals: Major | 15 | |
Precirix NV
 Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Aro Biotherapeutics Co.
 Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.
10
| Holding Company | Biotechnology | 10 |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.
9
| Holding Company | Biotechnology | 9 |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.
8
| Holding Company | Biotechnology | 8 |
Hemab ApS
 Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020.
7
| Holding Company | Biotechnology | 7 |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.
6
| Holding Company | Biotechnology | 6 |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.
5
| Subsidiary | Medical Specialties | 5 |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Marten Steen via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
Odlander, Fredrikson & Co. AB
 Odlander, Fredrikson & Co. AB Financial ConglomeratesFinance Odlander Fredrikson & Co. AB provides financial support services. The company was founded in 1996 and is headquartered in Stockholm, Sweden. | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman Chief Executive Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Healthcap 1999 GP AB
 Healthcap 1999 GP AB Investment Banks/BrokersFinance Part of Odlander, Fredrikson & Co. AB, Healthcap 1999 GP AB is a company that manages and trades securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | President Director/Board Member Director/Board Member Director/Board Member | |
LTB4 Sweden AB
 LTB4 Sweden AB BiotechnologyHealth Technology LTB4 Sweden AB engages in research and product development related to antimicrobial and anti-inflammatory substances through its subsidiaries. The company was founded by Bengt Ingemar Samuelsson on February 26, 2004 and is headquartered in Stockholm, Sweden. | Biotechnology | Founder Director/Board Member Chairman Chief Executive Officer | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman President | |
| BIOTAGE AB | Medical Specialties | Director/Board Member Founder Chief Executive Officer Director/Board Member | |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer Founder Founder Founder | |
Mariana Oncology, Inc.
 Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Biotechnology | Director of Finance/CFO Director/Board Member Director/Board Member | |
Nordic Vision Clinics AS
 Nordic Vision Clinics AS Hospital/Nursing ManagementHealth Services Part of NVC Holding AB, Nordic Vision Clinics AS is a Norwegian company that provides laser eye surgery. The company is based in Oslo, Norway. | Hospital/Nursing Management | Director/Board Member Chief Executive Officer Director/Board Member | |
NVC Holding AB
 NVC Holding AB Investment Banks/BrokersFinance NVC Holding AB owns and manages shares in companies and real property. The company is headquartered in Stockholm, Sweden. | Investment Banks/Brokers | Director/Board Member Chief Executive Officer Director/Board Member | |
| University of Oslo | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Founder Chief Executive Officer Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact Director/Board Member | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
| MACROGENICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director/Board Member | |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| Royal Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| University of Uppsala | College/University | Masters Business Admin Doctorate Degree Graduate Degree | |
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Operating Officer | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Healthcap Orx Holdings Gp AB
 Healthcap Orx Holdings Gp AB Investment Banks/BrokersFinance Healthcap Orx Holdings Gp AB is a private company that manages securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Chairman Director/Board Member Director/Board Member | |
Doctrin AB
 Doctrin AB Internet Software/ServicesTechnology Services Doctrin AB offers consultancy services within healthcare sector. It offers digital solutions that enable healthcare providers to prioritize, treat, and follow-up with their patients. The company was founded by Per Eriksson, Ashkan Labaf, Magnus Liungman, and Carslo Lorente in 2016 and is headquartered in Stockholm, Sweden. | Internet Software/Services | Corporate Officer/Principal Director/Board Member Director/Board Member | |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Healthcap Aero Holdings Gp | Director/Board Member Director/Board Member | ||
SEB Venture Capital
 SEB Venture Capital Investment ManagersFinance SEB Venture Capital (SEB Venture Capital) is a venture capital subsidiary of Skandinaviska Enskilda Banken AB founded in 1995. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Alba Therapeutics Corp.
 Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
A3P Biomedical AB
 A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Medical/Nursing Services | Director/Board Member Director of Finance/CFO | |
| University of Stockholm | College/University | Undergraduate Degree Undergraduate Degree | |
| FUSN PHAR | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Chairman Director/Board Member |
Statistiques
Internationale
| Suède | 28 |
| Etats-Unis | 11 |
| Norvège | 5 |
| France | 4 |
| Suisse | 3 |
Sectorielle
| Health Technology | 27 |
| Commercial Services | 9 |
| Consumer Services | 7 |
| Finance | 6 |
| Health Services | 4 |
Opérationnelle
| Director/Board Member | 735 |
| Corporate Officer/Principal | 193 |
| Independent Dir/Board Member | 135 |
| Chairman | 132 |
| Chief Executive Officer | 94 |
Relations les plus connectées
| Insiders | |
|---|---|
| Björn Ingemar Odlander | 53 |
| Eugen Steiner | 44 |
| John Maraganore | 38 |
| Oern Stuge | 38 |
| Per Anders Göte Samuelsson | 36 |
| Johan Rutger Christenson | 35 |
| Carl Erik Mathias Uhlén | 32 |
| Camille Samuels | 30 |
| Chris Mirabelli | 29 |
| Henry Skinner | 29 |
| Florent Gros | 28 |
| Bruce Peacock | 28 |
| Lionel Carnot | 27 |
| Luc Dochez | 26 |
| Carole Nüchterlein | 26 |
- Bourse
- Insiders
- Marten Steen
- Connexions Sociétés
